Spravato
Articles tagged with “Spravato”
FDA Esketamine (Spravato) Updates
A summary of the latest FDA regulatory actions, label updates, and clinical developments related to esketamine (Spravato) for depression treatment.
Ketamine Insurance Coverage: 2025 Trends and Developments
A look at the evolving insurance landscape for ketamine therapy in 2025, including Spravato coverage changes, off-label coverage, and what patients should know.
Racemic Ketamine vs Esketamine: Pharmacological Comparison
A detailed pharmacological comparison of racemic ketamine and esketamine (Spravato), covering efficacy, mechanisms, cost, access, and clinical decision-making.
Intranasal Ketamine and Esketamine (Spravato)
A comprehensive guide to intranasal ketamine therapy, including the FDA-approved esketamine nasal spray Spravato — how it works, the REMS program, and clinical considerations.
IV vs Oral vs Nasal Ketamine: Comparing Treatment Methods
A detailed comparison of IV infusion, oral/sublingual, and intranasal ketamine therapy methods covering effectiveness, cost, and convenience.
Esketamine: The S-Enantiomer Behind Spravato
A glossary entry on esketamine, the S-enantiomer of ketamine marketed as Spravato, covering its pharmacology, FDA approval, and clinical significance.
How Much Does Ketamine Therapy Cost?
A comprehensive breakdown of ketamine therapy costs by treatment type — IV infusion, Spravato, compounded formulations, and at-home options — plus factors that affect price.
Does Insurance Cover Ketamine Treatment?
A clear guide to insurance coverage for ketamine therapy, including Spravato, off-label IV infusions, and compounded formulations — plus tips for navigating coverage.
Esketamine vs Racemic Ketamine: Understanding the Difference
A clinical comparison of esketamine (Spravato) and racemic ketamine, covering the S-enantiomer vs R/S mixture, FDA approval, efficacy data, cost, and practical considerations.
Ready to learn more?
Explore our comprehensive guides and tools to help you navigate your ketamine therapy journey.